title: Citicoline oral solution in glaucoma: is there a role in slowing disease progression?
abstract: OBJECTIVE
  To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma.
  
  
  METHODS
  Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years.
  
  
  RESULTS
  At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01).
  
  
  CONCLUSIONS
  This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.
authors.affiliation: Eye Clinic, San Paolo Hospital, University of Milan, IT-20142 Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Ottobelli
authors.forename: G L
authors.initials: GL
authors.lastname: Manni
authors.forename: M
authors.initials: M
authors.lastname: Centofanti
authors.forename: M
authors.initials: M
authors.lastname: Iester
authors.forename: F
authors.initials: F
authors.lastname: Allevena
authors.forename: L
authors.initials: L
authors.lastname: Rossetti
mesh_terms: D000284:Administration, Oral; D000368:Aged; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D008297:Male; D018697:Nootropic Agents / Q000008:administration & dosage; D011446:Prospective Studies; D016896:Treatment Outcome; D014794:Visual Fields
chemical_list: D018697:Nootropic Agents; D003566:Cytidine Diphosphate Choline